Diagnostic significance of microRNA-1255b-5p in prostate cancer patients and its effect on cancer cell function

Discerning between indolent and aggressive types is a big challenge of prostate cancer clinically to guide the adequate therapeutic regimen. We aimed to examine the relationship between miR-1255b-p expression and prostate cancer and elucidate the function of miR-1255b-5p in prostate cancer. miR-1255b-5p were measured using Quantitative Real-Time PCR from the blood 103 benign prostate hyperplasia (BPH) and 153 prostate cancer patients (117 indolent cases and 36 upgrading cases). Using receiver operating characteristic (ROC) curve analysis, the discriminating ability of miR-1255b-5p was accessed between BPH and prostate cancer participants, or indolent and aggressive type. Using CCK-8 and Transwell assays, the function of miR-1255b-5p on prostate cancer cells was investigated. The levels of miR-1255b-5p were significantly raised in prostate cancer patients when compared with BPH participants. MiR-1255b-5p level can distinguish prostate cancer patients from BPH or indolent type from aggressive type. Downregulation of miR-1255b-5p can suppress the proliferative, invasive, and migratory capacity, but this effect can be eradicated by <i>EPB41L1</i> inhibition. The measurement of miR-1255b-5p in blood may provide a new noninvasive approach for the diagnosis of prostate cancer. miR-1255b-5p may become a potential therapeutic target for prostate cancer.

临床中，区分前列腺癌的惰性亚型与侵袭性亚型是指导制定合理治疗方案的一大难题。本研究旨在探讨miR-1255b-p的表达与前列腺癌的关联，并阐明miR-1255b-5p在前列腺癌中的生物学功能。研究采用实时定量聚合酶链反应（Quantitative Real-Time PCR）检测了103例良性前列腺增生（benign prostate hyperplasia, BPH）患者与153例前列腺癌患者（其中117例为惰性病例，36例升级型侵袭性病例）的血液样本中miR-1255b-5p的表达水平。采用受试者工作特征（Receiver Operating Characteristic, ROC）曲线分析，评估miR-1255b-5p区分BPH患者与前列腺癌患者，以及区分惰性亚型与侵袭性亚型的诊断效能。本研究通过CCK-8实验与Transwell实验，探究了miR-1255b-5p对前列腺癌细胞增殖、侵袭及迁移能力的调控作用。与BPH患者相比，前列腺癌患者的血液中miR-1255b-5p表达水平显著升高。miR-1255b-5p的表达水平可有效区分前列腺癌患者与BPH患者，亦可区分惰性亚型与侵袭性亚型的前列腺癌患者。下调miR-1255b-5p的表达可抑制前列腺癌细胞的增殖、侵袭与迁移能力，但该效应可被<i>EPB41L1</i>的抑制所消除。血液中miR-1255b-5p的检测可为前列腺癌的无创诊断提供新的非侵入性手段。miR-1255b-5p有望成为前列腺癌潜在的治疗靶点。